 Lopinavirritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy. Lopinavirritonavir pharmacokinetics might prevent resistance development in patients who experience virological rebound after single-drug simplification. 